GlassScriptPhysician profile
James D Quarles
NPI 1629077326
$6,283.33
in general payments reported to CMS, 2019-2025
55 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $796 · 2021: $995 · 2022: $1,450 · 2023: $953 · 2024: $815 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $681.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $610.62 | 2019-2023 | |
| Glaxosmithkline, LLC. | $512.17 | 2019-2025 | Trelegy Ellipta |
| Uswm, LLC | $506.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.74 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $346.42 | 2019-2023 | Myrbetriq, Veozah |
| Abbvie INC. | $278.49 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $276.86 | 2019-2024 | Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $237.97 | 2021-2025 | |
| Pfizer INC. | $234.89 | 2019-2025 | |
| Novo Nordisk INC | $199.43 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Radius Health, INC. | $191.86 | 2019-2023 | Tymlos |
| Amgen INC. | $187.08 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $135.57 | 2019-2024 | Airsupra, Breztri |
| Neotract INC. | $131.24 | 2019 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Quarles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.